Skip to content

PTIX

Protagenic Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.95
−5.00%
Ask drillr
Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
P/E (Fwd)
EV/EBITDA
−0.3x
Market Cap
$1.76M
RSI (14)
67.5
1D Return
−5.00%
YTD Return
−18.46%
SummaryUpdated Jun 1, 2026

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) is a clinical-stage biopharmaceutical company founded to develop novel therapeutics for stress-related neuropsychiatric and mood disorders. The company went public in April 2021 and is headquartered in New York, New York. Protagenic is currently focused on advancing its lead compound PT00114 through clinical trials, representing a potentially breakthrough approach to treating conditions like depression, anxiety, PTSD, and drug addiction through a novel neurobiological mechanism.

Similar companies

Latest newsMore news →